The Experts below are selected from a list of 168 Experts worldwide ranked by ideXlab platform
Howard A. Zacur - One of the best experts on this subject based on the ideXlab platform.
-
The effect of monophasic combinations of Ethinyl Estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: A randomized trial
Contraception, 1995Co-Authors: Dean Moutos, Shannon Smith, Howard A. ZacurAbstract:The effects of different monophasic combinations of Ethinyl Estradiol and norethindrone on FSH, LH, sex hormone binding globulin, total testosterone, androstenedione, and dehydroepiandrosterone sulfate levels in non-obese, non-hirsute women were compared. Retrospective analysis of frozen serum from a prospective randomized trial in which women received one of three oral contraceptive pills containing Ethinyl Estradiol 50 micrograms/norethindrone 1 mg, Ethinyl Estradiol 35 micrograms/norethindrone 1 mg or Ethinyl Estradiol 35 g/norethindrone 0.5 mg for nine cycles was conducted. Blood samples were obtained prior to treatment and during the third, sixth and ninth pill cycles. Ethinyl Estradiol 50 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 1 mg suppressed FSH, LH, and total testosterone and increased sex hormone binding globulin to a similar degree. Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg resulted in less suppression of FSH, LH, and total testosterone, but greater elevation of sex hormone binding globulin. Dehydroepiandrosterone sulfate was suppressed to a similar degree with Ethinyl Estradiol 35 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg, but Ethinyl Estradiol 50 micrograms/norethindrone 1 mg resulted in the least suppression of dehydroepiandrosterone sulfate. Ethinyl Estradiol 35 micrograms/norethindrone 1 mg caused greater suppression of androstenedione than did the other two oral contraceptives. Oral contraceptive-induced changes in gonadotropins, androgens, and sex hormone binding globulin can be predicted by considering the relative amounts of estrogen and progestin in the pill. When combined with 1 mg of norethindrone, 50 micrograms of Ethinyl Estradiol did not result in greater suppression of FSH, LH, or total testosterone or in greater elevation of sex hormone binding globulin than did 35 micrograms of Ethinyl Estradiol.
Thomas Rabe - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy and tolerability of norgestimate Ethinyl Estradiol 250 μg of norgestimate 35 μg of Ethinyl Estradiol results of an open multicenter study of 59 701 women
American Journal of Obstetrics and Gynecology, 1992Co-Authors: Benno Runnebaum, K. Grunwald, Thomas RabeAbstract:The efficacy and tolerability of a new oral contraceptive, norgestimate/Ethinyl Estradiol (250 μg of norgestimate/35 μg of Ethinyl Estradiol; Cilag GmbH Research, Sulzbach, Germany) were examined in an open-label study of 59,701 women who were evaluated during 342,348 menstrual cycles; 42,022 women completed the planned treatment regimen of six cycles. A use-efficacy (overall) Pearl index of 0.25 pregnancies per 100 woman-years was calculated based on 342,348 cycles. Tolerability was assessed for all women who completed six treatment cycles. Reductions in mean cycle length and duration of bleeding were noted; 32% of the women experienced reductions in the intensity of bleeding by the end of cycle 6. After six cycles of use, amenorrhea occurred in 1%, spotting in 4%, and breakthrough bleeding in 3% of the participating women. Treatment with norgestimate/Ethinyl Estradiol had minimal effects on weight, blood pressure, pulse, lipid metabolism, and blood glucose. Adverse effects (acne, nausea, or headaches) occurred at low frequencies and in many cases, were reduced compared with pretreatment levels. The results of this large-scale open trial were comparable with results from two other multicenter trials of the same formulation.
-
The efficacy and tolerability of norgestimate/Ethinyl Estradiol (250 μg of norgestimate/35 μg of Ethinyl Estradiol): Results of an open, multicenter study of 59,701 women
American Journal of Obstetrics and Gynecology, 1992Co-Authors: Benno Runnebaum, K. Grunwald, Thomas RabeAbstract:The efficacy and tolerability of a new oral contraceptive, norgestimate/Ethinyl Estradiol (250 μg of norgestimate/35 μg of Ethinyl Estradiol; Cilag GmbH Research, Sulzbach, Germany) were examined in an open-label study of 59,701 women who were evaluated during 342,348 menstrual cycles; 42,022 women completed the planned treatment regimen of six cycles. A use-efficacy (overall) Pearl index of 0.25 pregnancies per 100 woman-years was calculated based on 342,348 cycles. Tolerability was assessed for all women who completed six treatment cycles. Reductions in mean cycle length and duration of bleeding were noted; 32% of the women experienced reductions in the intensity of bleeding by the end of cycle 6. After six cycles of use, amenorrhea occurred in 1%, spotting in 4%, and breakthrough bleeding in 3% of the participating women. Treatment with norgestimate/Ethinyl Estradiol had minimal effects on weight, blood pressure, pulse, lipid metabolism, and blood glucose. Adverse effects (acne, nausea, or headaches) occurred at low frequencies and in many cases, were reduced compared with pretreatment levels. The results of this large-scale open trial were comparable with results from two other multicenter trials of the same formulation.
-
The efficacy and tolerability of norgestimate/Ethinyl Estradiol (250 micrograms of norgestimate/35 micrograms of Ethinyl Estradiol): results of an open, multicenter study of 59,701 women.
American journal of obstetrics and gynecology, 1992Co-Authors: Benno Runnebaum, K. Grunwald, Thomas RabeAbstract:The efficacy and tolerability of a new oral contraceptive, norgestimate/Ethinyl Estradiol (250 micrograms of norgestimate/35 micrograms of Ethinyl Estradiol; Cilag GmbH Research, Sulzbach, Germany) were examined in an open-label study of 59,701 women who were evaluated during 342,348 menstrual cycles; 42,022 women completed the planned treatment regimen of six cycles. A use-efficacy (overall) Pearl index of 0.25 pregnancies per 100 woman-years was calculated based on 342,348 cycles. Tolerability was assessed for all women who completed six treatment cycles. Reductions in mean cycle length and duration of bleeding were noted; 32% of the women experienced reductions in the intensity of bleeding by the end of cycle 6. After six cycles of use, amenorrhea occurred in 1%, spotting in 4%, and breakthrough bleeding in 3% of the participating women. Treatment with norgestimate/Ethinyl Estradiol had minimal effects on weight, blood pressure, pulse, lipid metabolism, and blood glucose. Adverse effects (acne, nausea, or headaches) occurred at low frequencies and in many cases, were reduced compared with pretreatment levels. The results of this large-scale open trial were comparable with results from two other multicenter trials of the same formulation.
Dean Moutos - One of the best experts on this subject based on the ideXlab platform.
-
The effect of monophasic combinations of Ethinyl Estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: A randomized trial
Contraception, 1995Co-Authors: Dean Moutos, Shannon Smith, Howard A. ZacurAbstract:The effects of different monophasic combinations of Ethinyl Estradiol and norethindrone on FSH, LH, sex hormone binding globulin, total testosterone, androstenedione, and dehydroepiandrosterone sulfate levels in non-obese, non-hirsute women were compared. Retrospective analysis of frozen serum from a prospective randomized trial in which women received one of three oral contraceptive pills containing Ethinyl Estradiol 50 micrograms/norethindrone 1 mg, Ethinyl Estradiol 35 micrograms/norethindrone 1 mg or Ethinyl Estradiol 35 g/norethindrone 0.5 mg for nine cycles was conducted. Blood samples were obtained prior to treatment and during the third, sixth and ninth pill cycles. Ethinyl Estradiol 50 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 1 mg suppressed FSH, LH, and total testosterone and increased sex hormone binding globulin to a similar degree. Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg resulted in less suppression of FSH, LH, and total testosterone, but greater elevation of sex hormone binding globulin. Dehydroepiandrosterone sulfate was suppressed to a similar degree with Ethinyl Estradiol 35 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg, but Ethinyl Estradiol 50 micrograms/norethindrone 1 mg resulted in the least suppression of dehydroepiandrosterone sulfate. Ethinyl Estradiol 35 micrograms/norethindrone 1 mg caused greater suppression of androstenedione than did the other two oral contraceptives. Oral contraceptive-induced changes in gonadotropins, androgens, and sex hormone binding globulin can be predicted by considering the relative amounts of estrogen and progestin in the pill. When combined with 1 mg of norethindrone, 50 micrograms of Ethinyl Estradiol did not result in greater suppression of FSH, LH, or total testosterone or in greater elevation of sex hormone binding globulin than did 35 micrograms of Ethinyl Estradiol.
Shannon Smith - One of the best experts on this subject based on the ideXlab platform.
-
The effect of monophasic combinations of Ethinyl Estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: A randomized trial
Contraception, 1995Co-Authors: Dean Moutos, Shannon Smith, Howard A. ZacurAbstract:The effects of different monophasic combinations of Ethinyl Estradiol and norethindrone on FSH, LH, sex hormone binding globulin, total testosterone, androstenedione, and dehydroepiandrosterone sulfate levels in non-obese, non-hirsute women were compared. Retrospective analysis of frozen serum from a prospective randomized trial in which women received one of three oral contraceptive pills containing Ethinyl Estradiol 50 micrograms/norethindrone 1 mg, Ethinyl Estradiol 35 micrograms/norethindrone 1 mg or Ethinyl Estradiol 35 g/norethindrone 0.5 mg for nine cycles was conducted. Blood samples were obtained prior to treatment and during the third, sixth and ninth pill cycles. Ethinyl Estradiol 50 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 1 mg suppressed FSH, LH, and total testosterone and increased sex hormone binding globulin to a similar degree. Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg resulted in less suppression of FSH, LH, and total testosterone, but greater elevation of sex hormone binding globulin. Dehydroepiandrosterone sulfate was suppressed to a similar degree with Ethinyl Estradiol 35 micrograms/norethindrone 1 mg and Ethinyl Estradiol 35 micrograms/norethindrone 0.5 mg, but Ethinyl Estradiol 50 micrograms/norethindrone 1 mg resulted in the least suppression of dehydroepiandrosterone sulfate. Ethinyl Estradiol 35 micrograms/norethindrone 1 mg caused greater suppression of androstenedione than did the other two oral contraceptives. Oral contraceptive-induced changes in gonadotropins, androgens, and sex hormone binding globulin can be predicted by considering the relative amounts of estrogen and progestin in the pill. When combined with 1 mg of norethindrone, 50 micrograms of Ethinyl Estradiol did not result in greater suppression of FSH, LH, or total testosterone or in greater elevation of sex hormone binding globulin than did 35 micrograms of Ethinyl Estradiol.
M J Gast - One of the best experts on this subject based on the ideXlab platform.
-
A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg Ethinyl Estradiol or triphasic norethindrone with Ethinyl Estradiol
American Journal of Obstetrics and Gynecology, 1999Co-Authors: H Reisman, D Martin, M J GastAbstract:Abstract Objective: This study was undertaken to compare the effects of 2 oral contraceptive regimens on menstrual cycle control and laboratory findings. Methods: In a multicenter randomized study 100 μg levonorgestrel with 20 μg Ethinyl Estradiol (Alesse or Loette) was given to 155 healthy women. A triphasic preparation of 500, 750, and 1000 μg norethindrone with 35 μg Ethinyl Estradiol (Ortho-Novum 7/7/7 or TriNovum) was given to 167 women for 1 to 4 cycles of treatment. Results: Overall, the percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding were similar between the 2 treatment groups. In the levonorgestrel with Ethinyl Estradiol group, there was a statistically significantly longer latent period and a statistically significantly shorter withdrawal bleeding episode. Adverse events were similar between treatment groups, and none were serious. Most mean changes from baseline laboratory values were comparable between groups, although the mean increase in cholesterol concentration was statistically significantly lower in the levonorgestrel with Ethinyl Estradiol group. Changes in triglyceride and glucose concentrations were not statistically significantly different between groups. Conclusions: Levonorgestrel (100 μg) with Ethinyl Estradiol (20 μg) provides menstrual cycle control equivalent to that obtained with triphasic norethindrone with Ethinyl Estradiol (75% higher estrogen dose) with similar safety and tolerability. (Am J Obstet Gynecol 1999;181:S45-52.)
-
A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg Ethinyl Estradiol or triphasic norethindrone with Ethinyl Estradiol.
American journal of obstetrics and gynecology, 1999Co-Authors: H Reisman, D Martin, M J GastAbstract:This study was undertaken to compare the effects of 2 oral contraceptive regimens on menstrual cycle control and laboratory findings. In a multicenter randomized study 100 microg levonorgestrel with 20 microg Ethinyl Estradiol (Alesse or Loette) was given to 155 healthy women. A triphasic preparation of 500, 750, and 1000 microg norethindrone with 35 microg Ethinyl Estradiol (Ortho-Novum 7/7/7 or TriNovum) was given to 167 women for 1 to 4 cycles of treatment. Overall, the percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding were similar between the 2 treatment groups. In the levonorgestrel with Ethinyl Estradiol group, there was a statistically significantly longer latent period and a statistically significantly shorter withdrawal bleeding episode. Adverse events were similar between treatment groups, and none were serious. Most mean changes from baseline laboratory values were comparable between groups, although the mean increase in cholesterol concentration was statistically significantly lower in the levonorgestrel with Ethinyl Estradiol group. Changes in triglyceride and glucose concentrations were not statistically significantly different between groups. Levonorgestrel (100 microg) with Ethinyl Estradiol (20 microg) provides menstrual cycle control equivalent to that obtained with triphasic norethindrone with Ethinyl Estradiol (75% higher estrogen dose) with similar safety and tolerability.
